This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma (NHL) that primarily arises in the skin but may involve the viscera, lymphatic system

  • mycosis fungoides is the most common subtype of CTCL

NICE state (1):

  • Mogamulizumab is recommended, within its marketing authorisation, as an option for treating Sezary syndrome (SS) in adults who have had at least 1 systemic treatment
  • Mogamulizumab is recommended as an option for treating mycosis fungoides (MF) in adults, only if:
    • their condition is stage 2B or above and
    • they have had at least 2 systemic treatments

Notes (2,3):

  • MF is the most common subtype of CTCL, with 1,620 incidences reported in 2016 in the United States, and is often characterized by patches, plaques, and erythroderma. SS is a much more rare and aggressive leukemic variant of CTCL, with an incidence of 70 in the same year (3)
  • study evidence evaluated mogamulizumab (a novel CCR4 humanized monoclonal antibody) , in relapsed/refractory MF and SS, show a meaningful progression free survival (PFS) benefit
  • the Phase III MAVORIC study compared mogamulizumab to vorinostat, an FDA approved drug for this indication, in 372 patients
    • mogamulizumab was found to have a superior PFS with a median of 7.7 months compared to 3.1 months in the vorinostat arm, with a hazard ratio of 0.53, p<0.001
    • mogamulizumab was well tolerated with the most common AE being infusion-related reactions (32%), drug rash (20%), diarrhea (23%), and fatigue (22%)
  • use of mogamulizumab up to 50 days prior to allogeneic hematopoietic stem cell transplantation has been associated with an increased risk of severe acute graft-vs.-host disease, steroid-refractory graft-vs.-host disease, and mortality (3)

Reference:

  • NICE (December 2021). Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome
  • Blackmon AL, Pinter-Brown L. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection. Drug Des Devel Ther. 2020;14:3747-3754. Published 2020 Sep 16. doi:10.2147/DDDT.S185896
  • Watson S, Marx JB. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma. J Adv Pract Oncol. 2019;10(8):883-888. doi:10.6004/jadpro.2019.10.8.10

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.